Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303705 · ClinicalTrials.gov registry record · Phase 1
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01303705 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 13 participants.
The verdict
NCT01303705, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.
Interventions
- DRUG Cyclophosphamide
- RADIATION Radiation
- DRUG Anti-OX40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-10-14 |
| Est. Completion | 2016-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01303705
The ClinicalTrials.gov registry entry for NCT01303705 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01303705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01303705 about?
NCT01303705 is a clinical study titled "Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer". This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.
What is the current status of trial NCT01303705?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2010-10-14. Estimated completion is 2016-07-05.
What interventions are being tested in trial NCT01303705?
The interventions under investigation include: Cyclophosphamide (DRUG), Radiation (RADIATION), Anti-OX40 (DRUG).
Who is sponsoring clinical trial NCT01303705?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.